Results 81 to 90 of about 144,657 (253)
The pathophysiology of immune checkpoint inhibitor-related pneumonitis remains incompletely understood. We conducted single-cell and T-cell receptor transcriptomic sequencing on the bronchoalveolar lavage fluid from five patients with grade ≥2 immune ...
Zhening Zhang +9 more
doaj +1 more source
Immune Checkpoint Inhibitor–Related Myositis and Associated Triad Overlap Syndrome
Objective Immune checkpoint inhibitor (ICI) myositis is a rare but a highly morbid condition, particularly with the ICI myositis triad syndrome of myositis, myocarditis, and myasthenia gravis. We report the clinical characteristics of ICI myositis and all‐cause mortality in these patients.
Selene Rubino +9 more
wiley +1 more source
A swelling‐programmed micropatterned hydrogel guides adherent cells through a controlled transition from cell–matrix anchoring to cadherin‐mediated cell–cell compaction, enabling rapid assembly of high‐viability spheroids with defined size and morphology.
Han Gyeol Nam +8 more
wiley +1 more source
Objective The effect of frequent whole-body CT scans during immune checkpoint inhibitor (ICI) therapy on patients' anti-tumor immunity. Methods We conducted a retrospective clinical study aimed to investigate the correlation between the frequency of CT ...
Jigang Dong +5 more
doaj +1 more source
Engineered red blood cell‐derived extracellular vesicles (eRBCEVs) are synthesized via controlled microfluidic assembly from native RBC lipids, enabling tunable encapsulation of proteins, nucleic acids, nanoparticles, and viral vectors. The platform demonstrates reproducible nanoscale architecture, preserved membrane composition, and functional cargo ...
Chiranth K. Nagaraj +23 more
wiley +1 more source
Immune checkpoint inhibitor-related acral vasculitis
Commentary on « Ipilimumab induced vasculitis » by Padda A. et al., J Immunother Cancer. 2018;6:12. The authors diagnosed a small vessel vasculitis following treatment with anti-CTLA-4 (ipilimumab) for a resected stage III B/C melanoma.
Thibault Comont +4 more
doaj +1 more source
Nanoemulsion delivery of a TLR7 agonist enhances safety and promotes colocalization with Leishmania‐infected macrophages in skin lesions, enabling a ∼2‐log reduction in parasite burden. However, tissue‐level constraints and TLR‐driven regulatory feedback generate a mixed immune response that limits complete parasite clearance.
Carmen Palomino‐Cano +11 more
wiley +1 more source
Management of Immune Checkpoint Inhibitor Toxicities
Quentin Durrechou,1 Charlotte Domblides,1,2 Baptiste Sionneau,1 Felix Lefort,1 Amandine Quivy,1 Alain Ravaud,1 Marine Gross-Goupil,1 Amaury Daste1 1Department of Medical Oncology, Hôpital Saint-André, CHU Bordeaux-University of Bordeaux ...
Durrechou Q +7 more
doaj
Peritoneal carcinomatosis is a hard‐to‐treat spread of abdominal cancers that often returns after therapy. Nanoparticles were developed to retain an immune‐boosting drug in the abdomen. When combined with chemotherapy in mice, this approach eliminated tumors in many cases and prevented recurrence, helping the immune system mount a stronger, longer ...
Vanessa Chan +10 more
wiley +1 more source
BRAF-mutated colorectal cancer correlates with poor prognosis and limited response to standard treatments. Combining immune checkpoint inhibitors with BRAF/MEK inhibitors shows promise against BRAF-mutant melanoma in both preclinical and clinical trials.
Eunyoung Tak +10 more
doaj +1 more source

